Heat Biologics, Inc. (NASDAQ:HTBX) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,180,000 shares, a drop of 72.5% from the December 15th total of 7,940,000 shares. Currently, 9.9% of the shares of the company are short sold. Based on an average daily trading volume, of 902,200 shares, the short-interest ratio is currently 2.4 days.
In other news, Director Edward B. Smith III sold 103,304 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $1.03, for a total value of $106,403.12. Following the completion of the sale, the director now directly owns 1,001 shares of the company’s stock, valued at $1,031.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.50% of the company’s stock.
Several large investors have recently bought and sold shares of HTBX. JPMorgan Chase & Co. purchased a new stake in Heat Biologics during the third quarter valued at about $34,000. Strategic Wealth Management Group LLC purchased a new position in shares of Heat Biologics in the third quarter worth about $53,000. State Street Corp purchased a new position in shares of Heat Biologics in the third quarter worth about $141,000. Morgan Stanley increased its holdings in shares of Heat Biologics by 138.6% in the third quarter. Morgan Stanley now owns 169,945 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 98,715 shares during the period. Finally, California Public Employees Retirement System purchased a new position in shares of Heat Biologics in the third quarter worth about $366,000. Hedge funds and other institutional investors own 5.86% of the company’s stock.
Heat Biologics (NASDAQ:HTBX) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Heat Biologics had a negative net margin of 527.90% and a negative return on equity of 44.07%. The business had revenue of $0.85 million during the quarter, compared to the consensus estimate of $0.59 million. Equities analysts predict that Heat Biologics will post -1.54 earnings per share for the current year.
A number of analysts have recently issued reports on HTBX shares. B. Riley reaffirmed a “buy” rating on shares of Heat Biologics in a research report on Thursday, December 24th. ValuEngine raised Heat Biologics from a “hold” rating to a “buy” rating in a research report on Friday, December 11th.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.
Featured Article: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.